Ivemend (Fosaprepitant)

Fosaprepitant is a prodrug that converts to aprepitant, which selectively blocks neurokinin‑1 (NK1) receptors. By preventing substance P from binding to these receptors in the brainstem's vomiting centre, it interrupts the signaling pathway that triggers chemotherapy‑induced nausea and vomiting.

The specific dose of Ivemend is determined by the prescribing clinician based on the chemotherapy regimen and patient characteristics. Typically, a single intravenous dose is given shortly before the start of chemotherapy, but the exact amount and timing are individualized.

Fosaprepitant is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It may be used during pregnancy only if the potential benefit outweighs the risk. Limited data exist for breastfeeding, so caution is advised and a risk‑benefit assessment should be performed.

To order Ivemend, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Ivemend (fosaprepitant) provides intravenous NK1 receptor blockade, offering rapid onset compared with oral aprepitant. It is often preferred when oral administration is not feasible or when a single‑dose IV regimen simplifies chemotherapy preparation. Compared with other NK1 antagonists such as netupitant/palonosetron, fosaprepitant has a similar efficacy profile but differs in formulation and dosing convenience.

Ivemend should be stored refrigerated at 2‑8 °C. Protect the vial from light, do not freeze, and avoid shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes and return to refrigeration promptly.

Ivemend is given as an intravenous infusion by a qualified healthcare professional. The solution is typically infused over 15‑30 minutes immediately before the start of chemotherapy. Administration guidelines, including infusion rate and monitoring, are provided in the product’s prescribing information.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, serious infusion‑related reactions (e.g., bronchospasm), cardiac arrhythmias or QT‑interval prolongation, and profound hypotension. Patients should be monitored closely during and after infusion for any signs of these events.

Ivemend is contraindicated in individuals with known hypersensitivity to fosaprepitant, aprepitant, or any excipients in the formulation. Caution is also advised for patients receiving strong CYP3A4 inducers, as efficacy may be reduced, and for those with severe hepatic impairment where careful monitoring is required.